• Bukwang Pharm’s third-quarter 2026 operating profit rose 120.7% year over year to KRW 2.16 billion.
• Revenue increased 21.2% from a year earlier to KRW 57.97 billion.
• Net profit fell 43.3% year over year to KRW 847 million.
• For January–September 2026, operating profit declined 22.2% year over year to KRW 4.68 billion.
• Nine-month net profit dropped 56.3% from a year earlier to KRW 3.4 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bukwang Pharm. Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261023800177), on October 23, 2026, and is solely responsible for the information contained therein.